TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30988169

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-TnT)
Number of subjects: 12310

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 12310

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 12310
Study: 29487995

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) + renal artery denervation (RDN)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 138
Study: 26994823

Group type: EXPERIMENTAL
Intervention: Combined strength and proprioception training (CSPT) program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daily activities (Control)
Number of subjects: 20
Study: 25509693

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22490110

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored feedback programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored feedback programme + prompts (e-mail and SMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information control condition
Number of subjects: 0
Study: 20580752

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study: 18717113

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15987349

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10; n = 79)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30; n = 87)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30)
Number of subjects: 166
Study: 12454557

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ethanol (0.03% < BAC < 0.05%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10473803

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage-colony stimulating factor (GM-CSF)
Number of subjects: 0
Study: 8768856

Group type: EXPERIMENTAL
Intervention: MK-386 (10-100 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg) + MK-386 (25 mg)
Number of subjects: 26
Study: 1725915

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg once daily, then 25 mg once daily, and finally 25 mg twice daily)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg once daily, then 240 mg once daily, and finally 240 mg twice daily)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg once daily and twice daily)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 369
Study: 6789593

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH)
Number of subjects: 0
Study: 30612463

Group type: EXPERIMENTAL
Intervention: 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine for 8 weeks
Number of subjects: 56
Study: 27762093

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 26850413

Group type: EXPERIMENTAL
Intervention: Collaborative care with a care manager (PCM)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Minimally enhanced usual care (MEU)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Engaged in care management
Number of subjects: 404
Study: 24433285

Group type: EXPERIMENTAL
Intervention: Febuxostat (10 mg/day for weeks 1-4, 20 mg/day for weeks 5-8, 40 mg/day from week 9 to week 108)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 22845636

Group type: EXPERIMENTAL
Intervention: One-to-one interaction process with group supportive psychotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 19261341

Group type: EXPERIMENTAL
Intervention: Dental treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no dental treatment)
Number of subjects: 30
Study: 17270577

Group type: EXPERIMENTAL
Intervention: Meditation-based stress management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anxiety disorder education program
Number of subjects: 0
Study: 15589377

Group type: EXPERIMENTAL
Intervention: Vitamin E 500 mg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vitamin E 1000 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12419152

Group type: EXPERIMENTAL
Intervention: BAG (bioactive glass) group
Number of subjects: 10

Group type: COMPARATOR
Intervention: OFD (open flap debridement) group
Number of subjects: 10
Study: 9459341

Group type: EXPERIMENTAL
Intervention: Allele II
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ala601‐Thr mutation on allele I
Number of subjects: 112
Study: 7657809

Group type: EXPERIMENTAL
Intervention: rPDGF-BB
Number of subjects: 0
Study: 2536288

Group type: EXPERIMENTAL
Intervention: Chemotherapy maintenance with MACC regimen (38 subjects)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Chemotherapy discontinuation (36 subjects)
Number of subjects: 116
Study: 27992256

Group type: EXPERIMENTAL
Intervention: Sensorimotor conditioning of the nondominant leg (4 sessions/wk; 3 wk)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control conditions (no conditioning)
Number of subjects: 23
Study: 29071382

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 90

Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 90
Study: 26327527

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 64
Study: 23342337

Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IOD) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Relined conventional denture (RCD) group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 20953817

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in the fourth quartile
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: CRP level as a continuous variable
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: Higher baseline CRP levels
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of CRP in troponin-positive patients
Number of subjects: 2974
Study: 18163409

Group type: EXPERIMENTAL
Intervention: People with Arthritis Can Exercise (PACE) program
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: People with Arthritis Can Exercise (PACE) program (attended >=9 classes)
Number of subjects: 346
Study: 16733670

Group type: EXPERIMENTAL
Intervention: Kalèdo board-game intervention (15-30 minute sessions once a week for 24 weeks)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no play sessions with Kalèdo)
Number of subjects: 241
Study: 14563577

Group type: EXPERIMENTAL
Intervention: Emergency revascularization (ERV)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Angiographic parameters (initial Thrombolysis in Myocardial Infarction flow grade, number of diseased vessels, culprit vessel)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 302
Study: 8788351

Group type: EXPERIMENTAL
Intervention: Intervention leaflet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 120
Study: 1337745

Group type: EXPERIMENTAL
Intervention: nedocromil sodium 2% eyedrops
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 6370030

Group type: EXPERIMENTAL
Intervention: Chlorprothixene 1 mg/kg i.m.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chlorprothixene 2 mg/kg orally
Number of subjects: 90

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 90
Study: 30630465

Group type: EXPERIMENTAL
Intervention: Locking blade nail (LBN)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Locking plate (PHILOS)
Number of subjects: 68
Study: 29189568

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27087109

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: VPA and MVPA
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (SB)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Substituting 5 min per day of SB, LPA or MPA with 5 min per day of VPA
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Substituting 5 min per day of VPA with SB or LPA
Number of subjects: 307
Study: 25096067

Group type: EXPERIMENTAL
Intervention: vemurafenib, 960 mg orally twice daily
Number of subjects: 675

Group type: COMPARATOR
Intervention: dacarbazine, 1,000 mg/m2 intravenously every 3 weeks
Number of subjects: 675
Study: 22419641

Group type: EXPERIMENTAL
Intervention: Rifampin (4 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoniazid (9 months)
Number of subjects: 0
Study: 19779355

Group type: EXPERIMENTAL
Intervention: HIVIGLOB/NVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIVNET 012
Number of subjects: 0
Study: 18004923

Group type: EXPERIMENTAL
Intervention: Verbal information using the illustration catalog and self application by the patient (I+A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Verbal information (V)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Verbal information with demonstration on model (M)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Verbal information with demonstration on model and self application by the patient (M+A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Verbal information using the illustration catalog (I)
Number of subjects: 150
Study: 15767288

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at baseline
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation during follow-up
Number of subjects: 3029
Study: 11939810

Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene gel applied twice daily (T + T)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene gel applied once daily and vehicle gel once daily (T + V)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Vehicle gel applied twice daily (V + V)
Number of subjects: 99
Study: 9873966

Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LMA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 20

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 20
Study: 8529320

Group type: EXPERIMENTAL
Intervention: Brachial artery pulse amplitudes with progressively compressive forces (0.45‐4.29N)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Radial artery pulse amplitudes with progressively compressive forces (0.45‐4.29N)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Applied forces up to 2.18 +/- 0.02N at brachial artery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Applied forces up to 2.59 +/- 0.02N at radial artery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Radial artery pulses at and beyond a force of 2.99 +/- 0.01N
Number of subjects: 10
Study: 2355823

Group type: EXPERIMENTAL
Intervention: Phosphate loading (1000 mg of tribasic sodium phosphate, four times daily for 6 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phosphate loading
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 122406

Group type: EXPERIMENTAL
Intervention: 0.5 mg haloperidol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 88 IU human LH (hLH)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prolactin plus luteinizing hormone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 5
Study: 30939483

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Number of subjects: 0
Study: 27921139

Group type: EXPERIMENTAL
Intervention: PCSO-524®
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 26469104

Group type: EXPERIMENTAL
Intervention: CYP2C9*2 and/or *3 genotypes
Number of subjects: 43

Group type: COMPARATOR
Intervention: CYP2C9*1/*1 genotype (Control)
Number of subjects: 43
Study: 23187044

Group type: EXPERIMENTAL
Intervention: Paraffin bath therapy (5 times per week, for 3-week duration)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no paraffin bath therapy)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Paraffin bath therapy
Number of subjects: 56
Study: 22025157

Group type: COMPARATOR
Intervention: Erlotinib (150 mg orally once a day) + Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once a day) + R1507 (9 mg/kg weekly)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once a day) + R1507 (16 mg/kg every 3 weeks)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: R1507 (9 mg/kg weekly)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 18481717

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with He-Ne laser radiation
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 97
Study: 16329770

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 120
Study: 12045122

Group type: EXPERIMENTAL
Intervention: Prolastin (60 mg/kg) administered in four infusions at weekly intervals
Number of subjects: 12
Study: 10213433

Group type: EXPERIMENTAL
Intervention: 3 microg/mL(‐1) of PPF and 0.5 ng/mL(‐1) of SUF in group I (GI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 microg/mL(‐1) of PPF and 1 ng/mL(‐1) of SUF in group II (GII)
Number of subjects: 20
Study: 7789477

Group type: EXPERIMENTAL
Intervention: Urinary LTE4 concentration after returning to Davos from The Netherlands
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PC20FEV1 after returning to Davos from The Netherlands
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FEV1 after returning to Davos from The Netherlands
Number of subjects: 14
Study: 2141775

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 26
Study: 655282

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 28704267

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (self-assessment leaflet)
Number of subjects: 263
Study: 29133320

Group type: EXPERIMENTAL
Intervention: Intensive 3-week home-based preoperative exercise training programme (R group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual physical therapy (Control group)
Number of subjects: 90
Study: 25922251

Group type: EXPERIMENTAL
Intervention: Dedicated cold snare
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional cold snare
Number of subjects: 76
Study: 23629602

Group type: EXPERIMENTAL
Intervention: CTHA/CTAP
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 21039929

Group type: EXPERIMENTAL
Intervention: 0.8% black tea extract (BTE) diet
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.4% black tea extract (BTE) diet
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control diet (0% BTE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: In vitro study with BTE
Number of subjects: 96
Study: 19253234

Group type: EXPERIMENTAL
Intervention: High-dose isotretinoin (>0.5 mg/kg per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose isotretinoin (<0.5 mg/kg per day)
Number of subjects: 51
Study: 17290375

Group type: EXPERIMENTAL
Intervention: Caffeine (morning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (morning)
Number of subjects: 0
Study: 15495821

Group type: EXPERIMENTAL
Intervention: Puerarin injection (500 mg per day for 2 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 61
Study: 11560455

Group type: EXPERIMENTAL
Intervention: bupropion, 300 mg/d
Number of subjects: 784
Study: 9783890

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 960

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: High dose-volume group
Number of subjects: 960
Study: 7923670

Group type: EXPERIMENTAL
Intervention: 60-microF capacitors
Number of subjects: 67

Group type: COMPARATOR
Intervention: 120-microF capacitors
Number of subjects: 67
Study: 3169110

Group type: EXPERIMENTAL
Intervention: Cicloprolol 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cicloprolol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cicloprolol 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cicloprolol (up to 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cicloprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenalterol 50 mg
Number of subjects: 0
Study: 29601367

Group type: EXPERIMENTAL
Intervention: BrainHQ (8-week, 40-hour program individualized to each patient's performance)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Active control computer-based crossword puzzles
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 264
Study: 27295179

Group type: EXPERIMENTAL
Intervention: Triple P parenting intervention
Number of subjects: 107
Study: 26265125

Group type: EXPERIMENTAL
Intervention: Mannitol treatment (n=1533)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Nonmannitol treatment (n=993)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Mannitol treatment in patients with larger baseline hematomas (≥15 mL)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Mannitol treatment
Number of subjects: 2839
Study: 23765639

Group type: COMPARATOR
Intervention: Vardenafil (10 mg/day, for 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil or Vardenafil
Number of subjects: 0
Study: 21037437

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 19087497

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (CRH)
Number of subjects: 44
Study: 15040559

Group type: EXPERIMENTAL
Intervention: AQ/SP
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: CQ/SP
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: SP
Number of subjects: 265
Study: 11848258

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg) and Indapamide (0.625 mg)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 471
Study: 9544371

Group type: EXPERIMENTAL
Intervention: General anesthesia (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anesthesia (Group B)
Number of subjects: 0
Study: 7851264

Group type: EXPERIMENTAL
Intervention: Individualized learning activity packages
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classroom instruction
Number of subjects: 40
Study: 2894399

Group type: EXPERIMENTAL
Intervention: DTP-AC vaccine
Number of subjects: 39

Group type: COMPARATOR
Intervention: DTP-WC vaccine
Number of subjects: 39
Study: 29102669

Group type: EXPERIMENTAL
Intervention: Inhalation of filtered air containing particulate mixture (PM 10, PM 2.5, PM 1.0 and PM 0.5 µm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhalation of filtered air mixture (control)
Number of subjects: 12
Study: 27377521

Group type: EXPERIMENTAL
Intervention: Single-Dose (SID) bowel preparation
Number of subjects: 341

Group type: COMPARATOR
Intervention: Split-Dose (SPD1) bowel preparation
Number of subjects: 341

Group type: COMPARATOR
Intervention: Split-Dose (SPD2) bowel preparation
Number of subjects: 341
Study: 24526078

Group type: EXPERIMENTAL
Intervention: Increased professional fluoride application (IPFA) programme
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Non-operative caries treatment and prevention (NOCTP) programme
Number of subjects: 230

Group type: COMPARATOR
Intervention: Regular dental care
Number of subjects: 230
Study: 23363790

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with dendritic cell and cytokine-induced killer cell (DC-CIK) immunotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 60